A closer look at the technologies used by LabGenius
LabGenius
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
100 Drummond Road, London, Greater Londo...Phone Number
+44 2036277156Website
www.labgeni.usRevenue
$12.7 MillionIndustry
About LabGenius
LabGenius Therapeutics is at the forefront of antibody discovery, utilizing a closed-loop platform that integrates AI, robotic automation, and synthetic biology to develop next-generation therapeutic antibodies targeting solid tumors. Their innovative platform, EVA, allows for the rapid identification and optimization of complex therapeutic antibodies, addressing the challenges of conventional methods that often yield sub-optimal results. The company focuses on creating selectivity-enhanced antibodies with superior killing profiles for cancer treatment. LabGenius Therapeutics aims to revolutionize therapeutic antibody development through the combination of human and machine intelligence.Explore more
SIC Code 87,873NAICS Code 54,541Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to LabGenius
Compare insights from companies similar to LabGenius, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
LabGenius
$12.7M
51-200
Private
$73.2M
2012
N/A
LabGenius Tech Stack
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LabGenius
Sign Up For FreeTo access detailed company insights
LabGenius Therapeutics is at the forefront of antibody discovery, utilizing a closed-loop platform that integrates AI, robotic automation, and synthetic biology to develop next-generation therapeutic antibodies targeting solid tumors. Their innovative platform, EVA, allows for the rapid identification and optimization of complex therapeutic antibod... Read More
